Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Current Treatment Landscape for Second and Subsequent Lines of Therapy in Metastatic Urothelial Carcinoma

Learn how to personalize therapy with immune checkpoint inhibitors and antibody–drug conjugates for patients with urothelial carcinoma previously treated with platinum-based therapy.
person default
Thomas Powles, MBBS, MRCP, MD
Alain Ravaud, MD, PhD
Released: October 15, 2020

This program is divided into several short segments which you can step through using the Video Chapters widget.

Related Content

From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 24, 2020 Expired: November 23, 2021

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020

Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

Matthew Galsky, MD Released: November 19, 2020

In slides from Clinical Care Options (CCO), experts provide insights on the optimal treatment of advanced HCC

Mark Yarchoan, MD Released: November 19, 2020

Video Chapters

Supported by an educational grant from
Pfizer and EMD Serono, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.